Hepatitis vaccine for infants in Guinea-Bissau raises controversy.. Where do the limits of science and ethics stand?

In the first hours of a child's life, a small dose of the vaccine may provide protection that lasts for many years. But what happens when the timing of that dose becomes part of a scientific experiment, and some newborns are asked to wait to get it?

This question made Hepatitis vaccine A subject of health and moral controversy in Guinea-Bissau, after a proposed experiment on thousands of newborn babies raised objections from scientists and the World Health Organization, and ended with researchers not obtaining the necessary governmental approval to implement it.

This issue opens the door to a broader discussion about the precise equation between medicine’s need for research and experimentation, and the human right, especially in the most fragile stages of life, to obtain proven health prevention.

A controversial experience

Controversy has begun over a research project led by a group of Danish researchers, with US financial support and private sector partners, to study the potential health effects of the timing of hepatitis B vaccine administration at birth.

According to the published details, the proposed design was targeting about 14 A thousand births In Guinea-Bissau, they are divided into two groups; The first receives the vaccine dose immediately after birth, while the second receives it at six weeks.

The researchers sought to study what is known With non-specific effects of vaccinesThat is, health outcomes that may go beyond direct protection from the target disease, including mortality rates, some skin conditions, and neurodevelopmental disorders.

The research team defended this design by pointing out that receiving the vaccine at six weeks of age is consistent with the vaccination schedule in place in Guinea-Bissau, while the study would have tested the effect of adding a dose immediately after birth.

Here the point of contention arose: Is adherence to the existing national vaccination schedule sufficient to justify delaying a preventive dose recommended by international health authorities to be given immediately after birth?

Why did scientists object?

The danger of hepatitis B lies in its ability to be transmitted from a mother to her child during birth, and the possibility of it turning into a chronic infection that may later lead to cirrhosis or liver cancer.

And she confirms Global Health Organization The birth dose has a long record of safety and effectiveness, It prevents between 70% and 95% of cases of transmission of infection from mother to child.

In Guinea-Bissau, prevention is increasingly important; Estimates reported by the organization indicate that more than 12% of adults were living with chronic infection with the virus in 2022.

The organization had warned, in a statement issued on February 13, 2026, of the dangers of the proposed design of the experiment, noting that some children might be exposed to serious harm that could be avoided. The organization then expressed concerns regarding the scientific justifications for the study and its ethical guarantees, before the issue returned to the forefront with controversy over the approvals necessary for its implementation in October.

As for the researchers, they defended their project by pointing out that the birth dose had not yet been included in comprehensive routine vaccination in the country, and that children in the second group would have received the care available according to the national vaccination schedule.

But this interpretation left open the ethical question: Can limited health services be made a basis for research comparison, when a method of prevention is available that has proven its benefit?

This is where it becomes important Target 3.3 of Sustainable Development Goal 3, good health and well-being, which includes combating viral hepatitis by 2030. Progress towards this goal is linked to strengthening infection prevention, especially among children, whose effects may extend to later stages of their lives.

Science in the balance of morals

Count Clinical trials It is an essential tool for developing medical knowledge and evaluating health interventions, but it is based on controls related to informed consent, assessment of risks and benefits, and protection of participants, and these controls become even more important when research includes children who cannot make the decision to participate for themselves.

In the case of Guinea-Bissau, the project raised questions about the approvals of relevant authorities, the nature of ethical review, and the adequacy of child protection procedures.

Researchers involved in the study told a Danish research ethics committee that authorities in Guinea-Bissau had approved an updated design for the trial, but the government later denied approval for its implementation.

The proposed amendments included examining mothers for hepatitis B, excluding children of infected women from the trial and giving them the vaccine. However, the details of the amended protocol were not fully available for public review at the time.

These facts reveal the necessity of distinguishing between the approval of a research committee and the approval of the state on whose territory the experiment will be conducted. Protection of children begins before they enter any study, when its objectives, methods and risks are subject to an independent and clear review.

A decision that decides the fate of the experiment

On October 13, 2026, the transitional government of Guinea-Bissau announced that it had not approved the proposed experiment, denying reports that it had obtained a permit.

During a press conference in the capital, Bissau, Health Minister Kwenhin Nantoti stressed the need for research involving humans, especially children, to adhere to national legislation, ethical standards, and competent evaluation and approval mechanisms.

She also denied US Department of Health and Human Services The study must have obtained the necessary approval. Developments continued; On October 16, the Council of Ministers in Guinea-Bissau reaffirmed its rejection of the experiment, according to statements quoted by one of the researchers supervising it.

On October 19, the judicial police searched the headquarters of the Pandim Health Project and closed the refrigerator containing the vaccines designated for the study, as part of an investigation into the source of these doses and the procedures for obtaining, transporting and storing them. The inspection came after the government confirmed its refusal to implement the experiment.

According to the research team's statements, the study was stopped before it began, and no child received a dose of the vaccines allocated for it.

Health justice…a right for everyone

If stopping school has decided its fate in Guinea-Bissau, what about the children who are still waiting for the birth dose to be made available within the national vaccination program?

According to the World Health Organization, Guinea-Bissau has decided in 2024 to include hepatitis B vaccine at birth in its national schedule, with plans to begin implementation by 2028.

The organization expressed its readiness to support the country in accelerating this step, by examining pregnant women, improving vaccine cold chains, training health workers, and facilitating access to children born in health facilities and homes.

This response opens a space for understanding Health equity As the ability of medical systems to provide means of prevention for everyone, regardless of economic circumstances or place of birth.

From here you gain Target 3.8 of Sustainable Development Goal 3, good health and well-being, direct meaning; It calls for universal health coverage, including access to basic services and safe, effective and affordable medicines and vaccines.

This meaning is related to what I discussed The Earth Guards Foundation in its file on the role of good health in achieving sustainable developmentPrevention and access to health care are highlighted as foundations for human protection and enhancing the ability of societies to confront dangers.

Thus, the issue extends from a decision related to a specific experiment to a larger question about the responsibility of health institutions to deliver proven medical knowledge to those who need it.

Progress begins with human protection

The hepatitis vaccine issue in Guinea-Bissau reveals two interrelated aspects of medical progress. One is to seek to discover new knowledge, and the other is to ensure that human safety and rights remain the basis of this scientific endeavour.

Here the importance of what you are calling for emerges The Earth Guards Foundation From upholding moral values ​​in guiding scientific research, so that human protection and dignity become the basis for medical progress, and justice in access to health care becomes an integral part of the development process.

The proposed trial has been halted, but the need for prevention remains, as does the responsibility to develop health programs that make vaccines available to children in a timely manner.

Protection may begin with a small injection in the first hours of life, but it expresses a larger commitment: that human health be the goal of scientific research, and that the fruits of medical progress reach everyone.